



CAREER TALKS SERIES

Dr. Holger Reithinger

Partner at Forbion



"Why is becoming a Biotech Venture Capitalist the most attractive Career Option for Scientists?"

Close to half of modern medicines originate from small biotech start-ups which carry the risk of drug development and are the driver of innovation in the pharmaceutical industry. The majority of those companies are financially supported by Venture Capital. The lecture will give an overview about the industry, its dynamics and about the people who are predominantly scientists (MDs, PhDs) - and about opportunities for young professionals interested in such a career path.

Tuesday, 21 January 2020 at 17:00

Seminar Room, Institute of Molecular Biology (IMB) Ackermannweg 4, 55128 Mainz

All are welcome to attend

Do you want to meet Dr. Reithinger personally? Contact us at: ngc.mainz@gmail.com



Supported by the Gutenberg Nachwuchs Kolleg

